DTaP vaccine - Serum Institute of India

Drug Profile

DTaP vaccine - Serum Institute of India

Alternative Names: Acellular pertusis vaccines - Serum Institute of India; Diphtheria tetanus-acellular pertussis vaccine - Serum Institute of India

Latest Information Update: 03 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Serum Institute of India
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Diphtheria; Pertussis; Tetanus

Most Recent Events

  • 25 Jun 2018 Genkyotex and Serum Institute of India expand licensing agreement for Vaxiclase Platform to include USA, European Union, Canada and United Kingdom
  • 18 Jul 2017 Serum Institute of India completes a phase I trial for Diphtheria, Pertussis and Tetanus (Prevention) in India (IM) (CTRI2017-03-008003)
  • 04 Jul 2017 Serum completes enrolment in its phase I trial for Tetanus, Pertussis and Diphtheria (Prevention) in India before July 2017 (CTRI2017-03-008003)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top